Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Breast Cancer × eribulin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 50 Triple Negative Breast Neoplasms 13 Sarcoma 5 Neoplasm Metastasis 5 Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Urethral Neoplasms 2 Ureteral Neoplasms 2 Prostatic Neoplasms 2 Inflammatory Breast Neoplasms 2 HER2-negative Breast Cancer 2 Brain Neoplasms 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solitary Fibrous Tumors 1 Sarcoma, Ewing 1 Salivary Gland Neoplasms 1 Rhabdomyosarcoma 1 Recurrence 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neoplastic Cells, Circulating 1 Neoplasm, Residual 1 Liposarcoma 1 Leiomyosarcoma 1 Ketosis 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1

Interventions

Fulvestrant 7 olaparib 4 Capecitabine 4 pyrotinib 3 Docetaxel 3 Vinorelbine 2 Trastuzumab 2 Alpelisib 2 vandetanib 1 trastuzumab deruxtecan 1 talazoparib 1 sacituzumab govitecan 1 neratinib 1 liposomal doxorubicin 1 exemestane 1 eribulin 1 dalpiciclib 1 ceralasertib 1 cediranib 1 capivasertib 1 abemaciclib 1 Tablets 1 Moxifloxacin 1 Letrozole 1 Goserelin 1 Everolimus 1 Dasatinib 1 Cyclophosphamide 1 Cisplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05530057 2025-11-20

ESPERO

Seoul National University Hospital

Phase 2 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡